机械拉伸波形及频率对肺腺癌细胞增殖的影响

通过FX-4000柔性基底加载系统研究了不同波形及频率的周期性机械拉伸对人肺腺癌A 549细胞株增殖的影响,应用Im age-P ro图像处理软件对A 549细胞株在心形波、三角波及方波等拉伸应变下的增殖动力学变化进行了分析。实验表明:在co llagenⅠ基底膜上,应变0-25%,频率为20次/m in、40次/m in及60次/m in,加载时间为2 h时,与对照组比较,方波刺激组细胞生长明显受到抑制,三角波刺激组细胞增殖率无明显差异,心形波刺激组细胞增殖加快。研究表明:A 549细胞株对体外的生理应变作出响应时,方波与60次/m in频率的组合刺激抑制作用最佳,且加载时间越长抑制效果越好。可见,波形与频率的合理组合在抑制人肺腺癌细胞增殖的过程中起着重要作用。     

The influence of thymus factor X (TFX) and of anti-TFX globulin on the growth of Lewis lung carcinoma in mice

The influence of thymus factor X--TFX (Polfa) and an anti-TFX rabbit gammaglobulin (RATFX) on the growth of Lewis lung carcinoma in mice was studied. The preparations were administered subcutaneously into the peritumoral region. Tumor growth was significantly retarded in the RATFX-treated groups, while a low dose TFX therapy was ineffective. No significant differences in peritumoral inflammatory reaction in treated and untreated mice were found.     

沙芭特在非细菌性前列腺炎症中的抗炎、抗纤维化及促进上皮细胞凋亡作用的研究

目的 探讨锯叶棕果实提取物沙芭特在非细菌性前列腺炎中的效应及其机制.方法 前列腺上皮细胞RWPE-1经M1表型的单核巨噬细胞THP-1细胞上清液共培养,治疗组加用沙芭特(10μg/ml)培养,MTS检测细胞增殖,流式细胞术检测细胞凋亡,RT-PCR、ELISA及West-ern blot检测炎症、纤维化及凋亡相关的蛋白分子(IL-1β、IL-17、TNF-α、Fas、COX2、Bax、TGF-β、DDR1、α-SMA及CollagenⅠ)的表达.消痔灵前列腺注射诱导大鼠非细菌性前列腺炎模型,用von Frey纤维检测沙芭特治疗前后各组大鼠的痛觉敏感性,然后麻醉SD大鼠,腔静脉取血后摘取前列腺组织并称重,免疫组化及ELISA检测炎症因子的表达,masson染色检测纤维化.结果 沙芭特抑制RWPE-1的增殖并促进其凋亡.M1表型THP-1条件培养液能促进上皮细胞表达IL-1β、TNF-α及COX-2,沙芭特处理能抑制炎症刺激所致的炎症因子表达,Western blot检测表明沙芭特处理能抑制COX-2、DDR1、SMA及CollagenⅠ的表达,增加Fas及Cleaved-caspase 3的表达.消痔灵100μl每侧叶注射可以成功诱导前列腺炎症模型,沙芭特60mg/kg能减少大鼠前列腺组织炎症因子的表达,缩小前列腺体积,降低大鼠痛觉敏感性.结论 沙芭特能抑制前列腺上皮细胞RWPE-1的增殖并促进其凋亡,减小前列腺体积,抑制炎症因子及纤维化相关分子的表达,减轻前列腺炎症及纤维化从而起到治疗作用.     

Risk factors related to hospital mortality in patients with isolated traumatic acute subdural haematoma: analysis of 308 patients undergone surgery

Background Acute subdural haematoma （ASDH） is a common traumatic brain injury with a relatively high mortality rate. However, few studies have examined the factors predicting the outcome of isolated traumatic ASDH. This clinical study examined the hospital mortality and analyzed the risk factors for mortality in patients treated surgically for isolated traumatic ASDH.
Methods We collected 308 consecutive patients who underwent neurosurgery for isolated traumatic ASDH between January 1999 and December 2007 and used multivariate Logistic regression analysis to evaluate the influence of 11 clinical variables on hospital mortality.
Results The overall hospital mortality was 21.75% （67/308）. Age （OR=1.807）, preoperative Glasgow Coma Score （OR=0.316）, brain herniation （OR=2.181） and the time from trauma to decompression （OR=1.815） were independent predictors of death, while no independent association was observed between hospital mortality and haematoma volume, midline shift, acute brain swelling or brain herniation duration, although these variables were correlated with hospital mortality in univariate analyses.
Conclusions This study identified the risk factors for hospital mortality in patients who underwent surgical treatment for isolated traumatic ASDH. An increased risk of death occurs in patients who are over 50 years of age and have lower preoperative Glasgow Coma Scores, the presence of brain herniation and a long interval between trauma and decompression. The findings should help clinicians determine management criteria and improve survival.     

Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer

Background

Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal function and development, is implicated in several neurodegenerative conditions. Preliminary data suggest that a reduction of BDNF concentrations may lead to postchemotherapy cognitive impairment. We hypothesized that a single nucleotide polymorphism (rs6265) of the BDNF gene may predispose patients to cognitive impairment. This study aimed to evaluate the effect of BDNF gene polymorphism on chemotherapy-associated cognitive impairment.

Methods

Overall, 145 patients receiving chemotherapy for early-stage breast cancer (mean age: 50.8 ± 8.8 y; 82.1% Chinese) were recruited. Patients'' cognitive functions were assessed longitudinally using the validated Functional Assessment of Cancer Therapy–Cognitive Function (v.3) and an objective computerized tool, Headminder. Genotyping was performed using Sanger sequencing. Logistic regression was used to evaluate the association between BDNF Val66Met polymorphism and cognition after adjusting for ethnicity and clinically important covariates.

Results

Of the 145 patients, 54 (37%) reported cognitive impairment postchemotherapy. The Met/Met genotype was associated with statistically significant lower odds of developing cognitive impairment (odds ratio [OR] = 0.26; 95% CI: 0.08–0.92; P = .036). The Met carriers were less likely to experience impairment in the domains of verbal fluency (OR = 0.34; 95% CI: 0.12–0.90; P = .031) and multitasking ability (OR = 0.37; 95% CI: 0.15–0.91; P = .030) compared with the Val/Val homozygote. No associations were observed between Headminder and the BDNF Val66Met polymorphism.

Conclusions

This is the first study to provide evidence that carriers of the BDNF Met allele are protected against chemotherapy-associated cognitive impairment. Further studies are required to validate the findings.